Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer.

ABSTRACT: The mechanism by which trastuzumab-emtansine (T-DM1) causes systemic toxicities apart from trastuzumab alone is currently unknown. We hypothesized that the systemic toxicities from T-DM1 may have been caused by the free and active maytansine released from the lysed HER2+ tumor cells, and if so, they may correlate with the response to treatment and eventually disease-free survival or patient outcome. In a retrospective, observational study, we evaluated 73 patients from three centers in the United States and Canada with advanced HER2+ breast cancer that received at least one dose of T-DM1. Toxicity grades were summed to create a corresponding toxicity sum score (TSS), and its association with clinical outcomes was analyzed. A higher TSS was significantly associated with longer progression-f

SUBMITTER: Tang SC 

PROVIDER: S-EPMC8360077 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature